Small-molecule Klotho enhancers as novel treatment of neurodegeneration

Future Med Chem. 2012 Sep;4(13):1671-9. doi: 10.4155/fmc.12.134.

Abstract

The majority of neurodegenerative diseases have an important age component, and thus, understanding the molecular changes that occur during normal aging of the brain is of utmost relevance. In search for the basis of the age-related cognitive decline found in humans, monkeys and rodents, we study the rhesus monkey. Surprisingly, there is no loss of neurons in aged monkey brains. However, we reported white matter and myelin abnormalities in aged monkeys, similar to those observed in Alzheimer's disease and multiple sclerosis patients. In a microarray analysis comparing young and old monkey white matter, we discovered that Klotho is downregulated in the aged brain. We then asked whether there is a connection between the age-related cognitive decline, myelin abnormalities and Klotho downregulation. If such a connection is found, compounds that upregulate Klotho expression could become of therapeutic interest for the treatment of multiple sclerosis, and perhaps even Alzheimer's disease.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Aging / genetics
  • Animals
  • Brain / cytology
  • Brain / drug effects
  • Brain / metabolism
  • Brain / pathology
  • Drug Discovery / methods*
  • Gene Expression Regulation / drug effects*
  • Glucuronidase / genetics*
  • HEK293 Cells
  • Humans
  • Klotho Proteins
  • Macaca mulatta
  • Neurodegenerative Diseases / drug therapy*
  • Neurodegenerative Diseases / genetics*
  • Neurodegenerative Diseases / pathology
  • RNA, Messenger / genetics
  • Small Molecule Libraries / pharmacology*
  • Transcriptional Activation / drug effects

Substances

  • RNA, Messenger
  • Small Molecule Libraries
  • Glucuronidase
  • Klotho Proteins